---
layout: default
title: Ramipril
parent: 僅模型預測 (L5)
nav_order: 176
evidence_level: L5
indication_count: 10
---

# Ramipril
{: .fs-9 }

證據等級: **L5** | 預測適應症: **10** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

The `txgnn-pipeline` skill confirms the general workflow; the report format is already fully defined in my system prompt. I'll now generate the evaluation report directly.

---

# Ramipril: From Hypertension to Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia

## One-Sentence Summary

Ramipril is a well-established ACE inhibitor (angiotensin-converting enzyme inhibitor) used internationally for hypertension, heart failure, and renoprotection in diabetic nephropathy — though no Italy marketing authorization currently exists.
The TxGNN model predicts it may be effective for **pulmonary hypertension owing to lung disease and/or hypoxia** (Group 3 PH),
but the currently retrieved evidence comprises **0 clinical trials** and **20 publications** — all of which are general reviews on hypoxia biology with no direct study of Ramipril in this specific condition.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | Hypertension, heart failure, renoprotection (no Italy regulatory data on file) |
| Predicted New Indication | Pulmonary Hypertension Owing to Lung Disease and/or Hypoxia |
| TxGNN Prediction Score | 99.93% |
| Evidence Level | L5 |
| Italy Market Status | ✗ Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |

---

## Why is This Prediction Reasonable?

Detailed mechanism of action data is not available in the current Evidence Pack. Based on established pharmacological knowledge, Ramipril belongs to the ACE inhibitor class: it blocks the conversion of angiotensin I to angiotensin II, thereby reducing systemic vascular resistance, suppressing aldosterone secretion, and providing cardio- and nephroprotective effects. Its efficacy in hypertension, post-MI heart failure (HOPE trial, AIRE trial), and chronic kidney disease (REIN trial) is robustly documented in the global literature.

The theoretical rationale connecting Ramipril to Group 3 pulmonary hypertension is as follows: chronic hypoxia triggers sustained pulmonary vasoconstriction, a process partially mediated by elevated angiotensin II activity. ACE inhibition could theoretically attenuate this vasoconstriction and slow vascular remodeling. This represents a biologically credible hypothesis, but one that has not been tested in dedicated clinical trials for this indication.

Critically, the 20 retrieved publications are general hypoxia biology reviews covering neurodegeneration, cognitive impairment, HIF-1α signaling, cancer biology, and altitude physiology — **none directly investigates Ramipril or ACE inhibitors in pulmonary hypertension due to lung disease**. The TxGNN model appears to have made this match through an indirect "hypoxia" concept node in the knowledge graph, rather than from direct drug-disease evidence. Current standard-of-care for Group 3 PH relies on treating the underlying lung disease; targeted therapies (PDE5 inhibitors, endothelin receptor antagonists, prostacyclin analogues) are used cautiously and are not routine.

---

## Clinical Trial Evidence

Currently no related clinical trials registered for Ramipril in pulmonary hypertension owing to lung disease and/or hypoxia.

---

## Literature Evidence

All 20 retrieved publications are general hypoxia-mechanism reviews. None evaluates Ramipril therapeutically in this disease. The most contextually relevant items are listed below for background reference:

| PMID | Year | Type | Journal | Key Findings |
|------|------|------|---------|-------------|
| [11172576](https://pubmed.ncbi.nlm.nih.gov/11172576/) | 2000 | Review | Respiratory Care Clinics of North America | Foundational review of hypoxemia mechanisms: V/Q mismatch, hypoventilation, shunt — relevant background for Group 3 PH pathophysiology |
| [9446167](https://pubmed.ncbi.nlm.nih.gov/9446167/) | 1997 | Review | Revue Medicale de Liege | Hepatopulmonary syndrome — hypoxia-driven pulmonary vascular involvement as a secondary process |
| [40815459](https://pubmed.ncbi.nlm.nih.gov/40815459/) | 2025 | Review | Rev Med Inst Mex Seguro Social | Hypobaric hypoxia at altitude; physiological acclimatization mechanisms |
| [33862277](https://pubmed.ncbi.nlm.nih.gov/33862277/) | 2021 | Review | Ageing Research Reviews | Hypoxia and brain aging; neuroprotective vs. neurodegenerative effects |
| [34618295](https://pubmed.ncbi.nlm.nih.gov/34618295/) | 2022 | Review | Metabolic Brain Disease | Clinical and molecular mechanisms of cognitive impairment under acute/chronic hypoxia |
| [31961750](https://pubmed.ncbi.nlm.nih.gov/31961750/) | 2020 | Review | Annual Review of Immunology | HIF pathway in innate immunity and inflammatory hypoxia |
| [21328446](https://pubmed.ncbi.nlm.nih.gov/21328446/) | 2011 | Review | Journal of Cellular Biochemistry | Hypoxia-mediated biological control: metabolism, pH homeostasis, angiogenesis |
| [34535359](https://pubmed.ncbi.nlm.nih.gov/34535359/) | 2021 | Review | Clinical Oncology | Therapeutic modification of tumour hypoxia; radiation resistance |
| [28219680](https://pubmed.ncbi.nlm.nih.gov/28219680/) | 2017 | Review | Experimental Cell Research | HIF-mediated transcriptional repression mechanisms under hypoxia |
| [24557798](https://pubmed.ncbi.nlm.nih.gov/24557798/) | 2014 | Review | Journal of Applied Physiology | Translational hypoxia research overview |

> ⚠️ **Note**: None of the above publications directly study Ramipril in pulmonary hypertension. These are background references retrieved via keyword overlap with the disease concept. Direct drug-disease evidence is absent.

---

## Italy Market Information

Ramipril has no current marketing authorizations in Italy. No product-level regulatory data is available.

---

## Safety Considerations

Please refer to the package insert for safety information.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
Despite a high TxGNN prediction score (99.93%), the evidence level is L5 — model prediction only, with no clinical trials and no directly relevant literature linking Ramipril to Group 3 pulmonary hypertension. The prediction appears to arise from an indirect concept-level match in the knowledge graph, not from mechanistic or clinical evidence specific to this indication.

**To proceed, the following is needed:**
- A targeted literature search for "ramipril AND pulmonary hypertension" or "ACE inhibitor AND Group 3 pulmonary hypertension" to confirm the true evidence gap
- Mechanistic validation of the RAAS-hypoxic vasoconstriction link in Group 3 PH specifically (distinct from Group 1 PAH, where ACE inhibitors may worsen outcomes)
- Retrieval of Ramipril's full prescribing information (MOA, warnings, contraindications, DDI) from AIFA or EMA databases to enable a proper safety assessment
- Prioritization of higher-ranked candidates from this same Evidence Pack with stronger mechanistic rationale: **cerebral artery occlusion** (Rank 10, L3, Proceed with Guardrails — direct Ramipril human study at PMID 8797135) and **malignant hypertensive renal disease** (Rank 4, L4, Research Question — supported by the REIN trial as lateral evidence) are both more actionable repurposing hypotheses
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

